Related Experiment Videos
Fondaparinux: new preparation. No better than LMWH in preventing pulmonary embolism
Abstract:
(1) The reference treatment for preventing pulmonary embolism and vein thrombosis during surgery for hip fracture and hip or knee replacement is a low-molecular-weight heparin (LMWH), administered subcutaneously. (2) Fondaparinux, a heparin-derived anticoagulant, is also licensed for these indications, and administered subcutaneously. (3) Four trials versus enoxaparin, an LMWH, showed that fondaparinux is no more effective in terms of clinically relevant endpoints (mortality, pulmonary embolism, or symptomatic vein thrombosis). (4) The risk of haemorrhage is not substantially different from the risk seen with enoxaparin. (5) Other adverse effects are also similar. The same close monitoring is required for elderly patients, patients with renal failure, and patients with a low body-weight. (6) An LMWH remains the reference prophylaxis during major orthopaedic surgery with high risk of pulmonary embolism.
Related Concept Videos
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Venous Thrombosis III: Interprofessional Care
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...